BURLINGTON, Mass., Feb. 28 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies, Inc. (Nasdaq: PMTI) announced today the VisiLux1064(TM) Laser
Handpiece and the LuxIR(TM) Infrared Handpiece for the Palomar StarLux(TM)
Pulsed Light and Laser System, and the DermaType(TM) Skinphotometer, presented
at the American Academy of Dermatology's 63rd Annual Meeting in New Orleans.
The Lux1064 Nd:YAG Laser Handpiece was introduced in February 2004 for the
treatment of vascular lesions, including leg veins, telangiectasias, and other
conditions. The VisiLux1064(TM) Laser Handpiece is the next generation and
features a built-in, high resolution camera which projects an image of the
treatment area onto an LCD screen mounted on the handpiece. The LCD screen
provides real-time digital imaging for clear evaluation and treatment of leg
veins and other targets. The camera magnifies the treatment area to about 4.5
times the actual size and through a proprietary illumination system enhances
the image by contrasting the target against its background, for example, to
provide clear viewing of deep veins. This innovation offers unparalleled
visibility, treatment precision and ease of use while offering an additional
laser alternative to Palomar's specialized family of Lux Handpieces. Palomar
plans to begin shipments of the VisiLux1064(TM) Laser Handpiece by the end of
the year.
The LuxIR(TM) Infrared Handpiece delivers pulses of infrared light deep
into the dermis to create carefully controlled areas of elevated temperature.
This handpiece is pending FDA clearance for the temporary relief of muscle and
joint pain, muscle relaxation and increased circulation. Palomar also intends
to seek FDA clearance for creating a smoother, tighter skin appearance as the
technology has been shown to trigger a biological response which leads to
collagen remodeling in the dermis. Remodeled collagen can fill the skin to
smooth out fine wrinkles and minor sagging, and can also stimulate increased
collagen production to create visible long term results. This is the first
Palomar Handpiece to utilize infrared light for the treatment of skin
rejuvenation. Palomar plans to begin shipments of the LuxIR(TM) Infrared
Handpiece by the end of the year.
The DermaType(TM) Skinphotometer measures the melanin and blood content of
skin in a matter of seconds. With this device, physicians will be able to
quickly and accurately determine appropriate Palomar System settings for each
patient to insure the safest and most accurate treatments are provided. The
DermaType(TM) Skinphotometer can be used in conjunction with the Palomar
StarLux(TM), MediLux(TM) or EsteLux(R) Systems, resulting in treatments
perfectly tailored to the patient's individual skin type. This device is not
yet available for sale. Palomar intends to seek FDA clearance for this device
in the near future and begin shipments of the DermaType(TM) Skinphotometer
this summer.
Chief Executive Officer Joseph P. Caruso commented, "We remain a market
leader in the development of new technology. We continue to advance our
aesthetic products to meet the demands of the market while offering the most
accurate and safe treatments possible. These new product additions greatly
increase a physician's available treatment options and complement our business
model by providing numerous expansion opportunities through versatile,
innovative attachments and harmonizing accessories."
About Palomar Medical Technologies Inc:
Palomar is a leading researcher and developer of light-based systems for
cosmetic treatments. Palomar pioneered the optical hair removal field, when,
in 1997, it introduced the first high-powered laser hair removal system. Since
then, many of the major advances in light-based hair removal have been based
on Palomar technology. There are now millions of light-based cosmetic
procedures performed around the world every year in physician offices,
clinics, spas and salons. Palomar is testing many new and exciting
indications to further advance the hair removal market and other cosmetic
applications. Palomar is uniquely focused on developing proprietary light-
based technology for introduction to the mass markets. Palomar has an
agreement with The Gillette Company (NYSE: G) to develop and potentially
commercialize a patented home-use, light-based hair removal device for women,
and an agreement with Johnson & Johnson Consumer Companies to develop and
potentially commercialize home-use, light-based devices for reducing or
reshaping body fat including cellulite, reducing the appearance of skin aging,
and reducing or preventing acne.
For more information on Palomar and its products, visit Palomar's website
at http://www.palomarmedical.com. To continue receiving the most up-to-date
information and latest news on Palomar as it happens, sign up to receive
automatic e-mail alerts by going to the E-mail Alerts page in the Investor
Relations' section of the website.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, challenges in managing joint ventures and
research with third parties and government contracts, the impact of
competitive products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained for future
products, the results of litigation, difficulties in collecting royalties,
potential infringement of third-party intellectual property rights, and/or
other factors, which are detailed from time to time in the Company's SEC
reports, including the report on Form 10-K for the year ended December 31,
2003 and the Company's quarterly reports on Form 10-Q. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to release
publicly the result of any revisions to these forward-looking statements that
may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Contacts:
Investor Relations
Palomar Medical Technologies Inc
781-993-2411
ir@palomarmedical.com
SOURCE Palomar Medical Technologies, Inc.
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/107555.html
Related links:
http://www.palomarmedical.com
CONTACT:
Investor Relations of Palomar Medical
Technologies Inc, +1-781-993-2411, ir@palomarmedical.com
|
